A Dose-Finding Phase I Followed by a Phase II Study to Evaluate the Safety and Efficacy of Allogeneic NK-cell Combined with Chemotherapy in Patients with PDA or Cholangiocarcinoma After Surgery

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Natural killer cell therapy-Medigen Biotechnology Corporation (Primary) ; Folinic acid; Gemcitabine; Gimeracil/oteracil/tegafur; Oxaliplatin
Indications Cholangiocarcinoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Medigen Biotechnology Corporation

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com